GSK’s two-drug HIV Dovato treatment meets main goal in study

19

GlaxoSmithKline Plc’s two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.

http://feeds.reuters.com/~r/reuters/healthNews/~3/xW53OgPI-5s/gsks-two-drug-hiv-dovato-treatment-meets-main-goal-in-study-idUSKCN1U50KV

- Advertisement -